Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.78 -0.6%	$0.71	$0.51 ▼ $1.38	$75.61M	0.28	245,579 shs	102,105 shs
CNTX Context Therapeutics	$0.86 -1.5%	$0.74	$0.49 ▼ $2.62	$78.30M	1.89	182,435 shs	135,298 shs
FBRX Forte Biosciences	$11.26 -0.4%	$11.34	$4.11 ▼ $28.68	$140.68M	2.91	62,862 shs	92,723 shs
JAN JanOne		$2.57	$0.22 ▼ $5.26	$20.03M	2.16	229,417 shs	139,500 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	-0.62%	-0.47%	+5.51%	+12.86%	-37.54%
CNTX Context Therapeutics	-1.54%	-1.60%	+2.20%	+33.71%	-65.62%
FBRX Forte Biosciences	-0.44%	-4.17%	-2.93%	+16.44%	+83,431.16%
JAN JanOne	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	2.4877 of 5 stars	3.5	2.0	0.0	0.0	2.3	0.8	1.3
CNTX Context Therapeutics	3.4346 of 5 stars	3.6	4.0	0.0	0.0	2.7	1.7	1.3
FBRX Forte Biosciences	2.7311 of 5 stars	3.5	3.0	0.0	0.0	2.5	1.7	0.6
JAN JanOne	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	2.33	Hold	$2.38	204.18% Upside
CNTX Context Therapeutics	3.17	Buy	$5.25	510.82% Upside
FBRX Forte Biosciences	3.00	Buy	$68.00	503.91% Upside
JAN JanOne	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest JAN, FBRX, CNTX, and ASRT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	ASRT Assertio	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/18/2025	FBRX Forte Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$75.00
8/18/2025	FBRX Forte Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$75.00
8/15/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
8/12/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
8/7/2025	CNTX Context Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
8/7/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/26/2025	CNTX Context Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$4.50 ➝ $4.00
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$124.96M	0.60	$0.05 per share	16.00	$0.97 per share	0.80
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.92 per share	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$7.93 per share	N/A
JAN JanOne	$39.61M	0.00	N/A	N/A	($0.67) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$21.58M	-$0.45	N/A	26.03	N/A	-36.97%	-38.19%	-15.45%	11/10/2025 (Estimated)
CNTX Context Therapeutics	-$26.73M	-$0.36	N/A	N/A	N/A	N/A	-38.80%	-37.53%	11/5/2025 (Estimated)
FBRX Forte Biosciences	-$35.48M	-$16.29	N/A	N/A	N/A	N/A	-85.38%	-72.34%	11/13/2025 (Estimated)
JAN JanOne	-$7.81M	N/A	0.00	N/A	N/A	N/A	-359.71%	-70.26%	N/A

Latest JAN, FBRX, CNTX, and ASRT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FBRX Forte Biosciences	-$1.21	-$0.96	+$0.25	-$0.96	N/A	N/A
8/11/2025	Q2 2025	ASRT Assertio	-$0.10	-$0.17	-$0.07	-$0.17	$27.86 million	$29.22 million
8/6/2025	Q2 2025	CNTX Context Therapeutics	-$0.06	-$0.09	-$0.03	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
JAN JanOne	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.42	1.59	1.34
CNTX Context Therapeutics	N/A	19.09	19.09
FBRX Forte Biosciences	N/A	11.74	11.74
JAN JanOne	N/A	0.15	0.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
CNTX Context Therapeutics	14.03%
FBRX Forte Biosciences	77.63%
JAN JanOne	6.27%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
CNTX Context Therapeutics	3.04%
FBRX Forte Biosciences	5.90%
JAN JanOne	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	96.24 million	92.39 million	Optionable
CNTX Context Therapeutics	7	89.70 million	86.98 million	Not Optionable
FBRX Forte Biosciences	5	12.43 million	11.70 million	Optionable
JAN JanOne	170	8.98 million	8.71 million	Not Optionable

JAN, FBRX, CNTX, and ASRT Headlines

Recent News About These Companies

CSE Bulletin: New Listing - Giant Mining Corp. 14JAN2026 Warrants (BFG.WT.B)

May 20, 2025 | newsfilecorp.comN

Biotech Company Loses Insurance Appeal on SEC Probe Expenses

May 9, 2025 | news.bloomberglaw.comN

Appeals Court Grills Biotech, Insurer on SEC Probe Coverage

April 9, 2025 | news.bloomberglaw.comN

New Dayton-based publicly traded company in the works with prominent local leader

October 7, 2024 | bizjournals.com

L-L League field hockey capsules: Who's who in Section 2 for 2024

August 27, 2024 | lancasteronline.comL

JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTS

July 12, 2024 | prnewswire.com

JanOne Announces Plan to Enhance Stockholder Value Through Strategic Realignment

July 10, 2024 | prnewswire.com

3 Fintech Stocks to Sell in July Before They Crash & Burn

July 8, 2024 | investorplace.com

JanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 Sigma

June 26, 2024 | prnewswire.com

ALT5 SIGMA, A JANONE COMPANY, ADDS PREPAID VISA®️ CARD INTEGRATION TO ALT5 SETTLEMENT PLATFORM

June 25, 2024 | prnewswire.com

JanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024

June 13, 2024 | prnewswire.com

ALT5 Sigma, a wholly-owned subsidiary of JanOne, Launches ALT5 Settlement Platform aimed at the untapped $27.3 Billion Global Digital Content Creation Market

June 11, 2024 | prnewswire.com

JanOne Inc. added to the Russell Microcap® Index

June 3, 2024 | prnewswire.com

ALT 5 Sigma, a wholly-owned subsidiary of JanOne to Present at the iFX Expo, the World's largest online trading conference and tradeshow

May 28, 2024 | prnewswire.com

It’s not the right time to quit: JanOne Inc (JAN) Stock

May 27, 2024 | bovnews.comB

JanOne Inc. (JAN) Stock Price, News, Quote & History - Yahoo Finance

May 16, 2024 | finance.yahoo.com

JanOne Closes Acquisition of ALT 5 Sigma Inc., a Leading Next Generation Blockchain Fintech

May 16, 2024 | prnewswire.com

Why Tevogen Bio Holdings Stock Is Moving Higher Today

May 13, 2024 | msn.com

JanOne To Buy Block Chain Fintech Provider ALT 5 Sigma In All-stock Deal; JAN Up In Pre-market

May 13, 2024 | markets.businessinsider.com

Janone To Acquire Blockchain Fintech Provider ALT 5 Sigma

May 12, 2024 | crowdfundinsider.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAN, FBRX, CNTX, and ASRT Company Descriptions

Assertio NASDAQ:ASRT

$0.78 0.00 (-0.62%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$0.79 +0.01 (+0.67%)

As of 08:00 AM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Context Therapeutics NASDAQ:CNTX

$0.86 -0.01 (-1.54%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$0.88 +0.03 (+2.97%)

As of 08:00 AM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Forte Biosciences NASDAQ:FBRX

$11.26 -0.05 (-0.44%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$11.05 -0.21 (-1.90%)

As of 08/26/2025 07:31 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

JanOne NASDAQ:JAN

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time